Literature DB >> 22718927

Developing an effective treatment algorithm for rheumatoid arthritis.

Edward C Keystone1, Josef Smolen, Piet van Riel.   

Abstract

RA is defined by the interrelated triad of disease activity, joint damage and disability. Although disease activity and its associated disability are reversible, joint damage and its associated disability are not. Thus, an important goal of RA therapy is to maximally reduce disease activity and thereby mitigate the accumulation of irreversible joint damage. Treatment for patients with RA should be initiated early and aggressively, with frequent assessments and a goal of achieving remission as quickly as possible after treatment initiation. We propose a treatment algorithm that recommends early and aggressive therapy with high-dose MTX therapy (15-25 mg/week), which may include moderate doses of glucocorticoids. The goal is to achieve low disease activity (determined by a composite measure that includes joint counts) within 3-6 months. If low disease activity is not achieved by 6 months, another conventional DMARD or a biologic agent should be added to the treatment regimen or patients should be switched to another DMARD plus a glucocorticoid. Once low disease activity is achieved, the treatment goal for the ensuing 3-6 months becomes disease remission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718927     DOI: 10.1093/rheumatology/kes122

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  16 in total

1.  Evaluation of a Novel Semi-Automated Ultrasound System for the Detection of Synovitis: A Prospective Study involving 45 Patients with Rheumatoid Arthritis.

Authors:  M Witt; J Frielinghausen; R Mueller; F Mueller; F Proft; H Schulze-Koops; M Grunke; D-A Clevert
Journal:  Ultrasound Int Open       Date:  2016-09-14

2.  Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset.

Authors:  Jesse M Damsker; Michaelyn R Cornish; Priya Kanneboyina; Ila Kanneboyina; Qing Yu; Rachel Lipson; Aditi Phadke; Susan M Knoblach; Karuna Panchapakesan; Melissa Morales; Alyson A Fiorillo; Terence Partridge; Kanneboyina Nagaraju
Journal:  Inflamm Res       Date:  2019-08-24       Impact factor: 4.575

3.  Schizophrenia-like disorder associated with etanercept treatment.

Authors:  Onome Victor Atigari; David Healy
Journal:  BMJ Case Rep       Date:  2014-01-13

4.  Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends.

Authors:  Christopher B Atzinger; Jeff J Guo
Journal:  Am Health Drug Benefits       Date:  2017-02

5.  Brief Report: Treatment of Tumor Necrosis Factor-Transgenic Mice With Anti-Tumor Necrosis Factor Restores Lymphatic Contractions, Repairs Lymphatic Vessels, and May Increase Monocyte/Macrophage Egress.

Authors:  Echoe M Bouta; Igor Kuzin; Karen de Mesy Bentley; Ronald W Wood; Homaira Rahimi; Rui-Cheng Ji; Christopher T Ritchlin; Andrea Bottaro; Lianping Xing; Edward M Schwarz
Journal:  Arthritis Rheumatol       Date:  2017-04-04       Impact factor: 10.995

6.  Vitamin D and rheumatoid arthritis.

Authors:  Ifigenia Kostoglou-Athanassiou; Panagiotis Athanassiou; Aikaterini Lyraki; Ioannis Raftakis; Christodoulos Antoniadis
Journal:  Ther Adv Endocrinol Metab       Date:  2012-12       Impact factor: 3.565

7.  Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications.

Authors:  Sarah Patterson; Gabriela Schmajuk; Michael Evans; Ishita Aggarwal; Zara Izadi; Milena Gianfrancesco; Jinoos Yazdany
Journal:  Jt Comm J Qual Patient Saf       Date:  2019-01-25

8.  Green Tea Epigallocatechin-3-Gallate Suppresses Autoimmune Arthritis Through Indoleamine-2,3-Dioxygenase Expressing Dendritic Cells and the Nuclear Factor, Erythroid 2-Like 2 Antioxidant Pathway.

Authors:  Laurie S Davis; Chandra Mohan; So-Youn Min; Mei Yan; Sang Bum Kim; Sneha Ravikumar; Seong-Ryuel Kwon; Kamala Vanarsa; Ho-Youn Kim
Journal:  J Inflamm (Lond)       Date:  2015-09-15       Impact factor: 4.981

9.  Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis.

Authors:  Tuan Khai Huynh; Ann Ostergaard; Charlotte Egsmose; Ole Rintek Madsen
Journal:  Patient Prefer Adherence       Date:  2014-01-20       Impact factor: 2.711

Review 10.  Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis.

Authors:  Arthur Kavanaugh; Alvin F Wells
Journal:  Rheumatology (Oxford)       Date:  2014-04-10       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.